INTRODUCTION
Injection sclerotherapy is successful in controlling acute variceal bleeding in 85-95% of patients1'2. If bleeding persists immediately after completion of the sclerotherapy or recurs early (within 24 h), haemostasis can be achieved in the majority of cases by balloon tamponade of the oesophagus. However, tamponade of the oesophagus is associated with a complication rate of approximately 25 %3 and the risk of perforation or ulceration may be increased after injection sclerotherapy since the sclerosant renders the mucosa more friable4. Consequently, it has been recommended that mechanical compression of the oesophagus should not exceed 12 h after sclerotherapy3. Therefore if the patient continues to bleed or rebleeding occurs early after balloon tamponade instituted to control haemorrhage after injection sclerotherapy, there is a need for an alternative therapy to achieve haemostasis. In view of the reported efficacy of somatostatin in the control of acute variceal bleeding51, we describe our experience with the hormone in controlling significant bleeding from the varices after failed injection sclerotherapy and balloon tamponade.
PATIENTS AND METHODS
Between January 1985 12 17 with poor liver function
The results of the present study clearly indicate that somatostatin infusion is a very safe and effective treatment for the control of substantial variceal haemorrhage after failed injection sclerotherapy followed by 12 h balloon tamponade. Thus initial control of bleeding was achieved in 15 of the 16 patients without any undesirable side effects. The patient who rebled after 72 h of treatment with somatostatin (Child's B) had moderate liver dysfunction and bleeding was controlled by oesophageal transection from which she made an uneventful recovery. The one patient in which somatostatin failed to control the bleeding had severe liver dysfunction (Child's C) with large varices and haemostasis was not achieved by further injection sclerotherapy and balloon tamponade. Although bleeding was controlled by emergency oesophageal transection the patient died post-operatively from progressive hepato-renal failure, the usual outcome, of emergency surgery in patients with severe hepatic dysfunction. Therefore, overall somatostatin was effective in controlling post injection sclerotherapy in 87.5% of the patients.
The precise mechanism whereby somatostatin is effective in controlling variceal haemorrhage has not been fully established. Somatostatin has been demonstrated to reduce portal pressure in both experimental animals and in patients with cirrhosis18-2. However, perhaps more importantly, the hormone has a much greater effect on collateral and azygous blood flow than on portal pressure2122. Consequently, a reduction in collateral blood flow, including that through the varices may be a major factor in controlling hamorrhage. Furthermore, although erosion of the varices by reflux of gastric content is not thought to contribute to variceal bleeding per se, the marked inhibitory effect of sandostatin on basal and stimulated gastric secretion of acid and pepsin [22] [23] [24] may present clot dissolution and hence recurrent haemorrhage.
In summary therefore, somatostatin would appear to be a safe and effective therapy for the control of variceal bleeding after injection sclerotherapy. Clearly, however, further randomised controlled trials are necessary to substantiate this hypothesis. Furthermore, since the risk of rebleeding is greatest in the first 5 days after variceal haemorrhage23 '24, somatostatin In many publications, somatostatin and its longer-acting analogue, octreotide (Sandostatin), have been shown to be as effective or better than placebo, vasopressin, tamponade and acute sclerotherapy respectively in the early management of acute variceal bleeding. In this paper the extension of the use of these drugs to the management of post-iniection bleeding has produced encouraging results. In the Liverpool series only four patients per annum fall into the category of post injection bleeders, making a controlled trial impossible. Although only half of their patients were Child's Class C patients, the results are encouraging to surgeons reluctant to undertake operative salvage of these difficult patients. Elsewhere the authors have shown that somatostatin is effective whether post-injection bleeding is due to recurrent variceal bleeding, post-injection ulceration or oesophagitis. While waiting for further results from other centres, many of us have been encouraged to adopt octreotide (Sandostatin) therapy for these post-injection bleeders.
